COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,367 Articles (22,803 medRxiv, 8,564 bioRxiv)

Most recent first Page 1: Articles 1-10  | Next

Deep mutational scanning of recent SARS-CoV-2 variants highlights changing amino acid preferences within epistatic hotspot residues
Taylor, A., Starr, T. N.
10.64898/2026.03.11.711006 — Posted: 2026-03-13
Discovery of Semicarbazone and Thiosemicarbazone Analogs as Competitive SARS-CoV-2 Virus Main Protease (Mpro) Inhibitors
Barreto, L. V., Lourenco, E. M. G., da Silva, E. B., de Godoy, M. O., Martins, L. C., Laureano de Souza, M., Almeida, R. G., Cunha, V. L. S., Pires, M. C., Lavorato, S. N., de Souza, T. B., Bretas, A. C. O., Ottoni, F. M., Junior, E. N. S., Oliva, G., Alves, R. J., de Oliveira, R. B., Guido, R. V. C., Ferreira, R. S.
10.64898/2026.03.11.711159 — Posted: 2026-03-12
Persistent SARS-CoV-2 Spike is Associated with Localized Immune Dysregulation in Long COVID Gut Biopsies
Abraham Soria, S., Peterson, P., VanElzakker, M. B., Tankelevich, M., Mehandru, S., Proal, A., Putrino, D., Freire, M.
10.64898/2026.03.09.707564 — Posted: 2026-03-12
Preliminary stability studies of a ss-SARS-CoV-2 virus-like particle vaccine
Torresi, J., Edeling, M. A., Earnest-Silveira, L., Carrera, J., Yap, A. H. Y., Hans, D.
10.64898/2026.03.11.711036 — Posted: 2026-03-12
Constrained Diffusion as a Paradigm for Evolution
Lazarev, D., Sappington, A., Chau, G., Zhang, R., Berger, B.
10.64898/2026.03.10.710948 — Posted: 2026-03-11
Anthracyclines inhibit -1 programmed ribosomal frameshifting and restrict HCoV-OC43 infection
Scheller, D., Islam, K., Lindgren, L., Arnberg, N., Johansson, J.
10.64898/2026.03.08.709729 — Posted: 2026-03-10
One and Done: A safe, adaptable single-cycle SARS-CoV-2 vaccine platform blocks XBB.1.5 infection and transmission
Schoen, J., Halwe, N. J., Britzke, T., Breithaupt, A., Ulrich, L., Kochmann, J., Corleis, B., Kipfer, E. T., Klimkait, T., Hoffmann, D., Otte, F., Beer, M., Hauser, D.
10.64898/2026.03.09.709481 — Posted: 2026-03-10
A Universal, AI-based Design Framework for Efficient Manufacturing of mRNA Therapeutics
Liao, K.-C., Maccari, G., Ciano, G., Huber, R., von der Haar, T., Tham, C.-Y., Ting Xun Ong, N., Florez de Sessions, P., Yih Saw, T., Wei Lim, T., Martin, C., Dickman, M., Kis, Z., Makatsoris, H., van Asbeck, A., Wan, Y., Medini, D.
10.64898/2026.03.09.710039 — Posted: 2026-03-10
The serum from critical COVID-19 patients induces proteomic changes in olfactory neuroepithelial cells that resemble post-covid neurological complications
Beltran-Camacho, L., Bhosale, S., Hidalgo-Figueroa, M., Delgado-Sequera, A., Sanchez-Morillo, D., Perez-Revuelta, J., Romero Lopez-Alberca, C., Larsen, M., Moreno-Luna, R., Berrocoso, E., Duran-Ruiz, M. C.
10.64898/2026.03.09.710460 — Posted: 2026-03-10
Molecular Characterization of SARS-CoV-2 N Protein Interfaces: Implications for Oligomerization, RNA Binding, and Phase Separation
Bairy, S. G., Prasad, T. K., Saravana Kumar, Y., Ganavi, B., S, S., S, S., Baskaran, S. P., Sounderrajan, V., Parthasarathy, K., Kamariah, N.
10.64898/2026.03.06.710084 — Posted: 2026-03-06

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).